Zhu and his research team first analyzed the F proteins used in the development of four existing RSV vaccines—the commercially available Arexvy, mResvia and Abrysvo, and an experimental vaccine ...
The two vaccines induce the immune system to target a critical protein on the surface of RSV, the F protein, in its pre-infection form, known as pre-fusion F. High levels of antibodies against pre ...